Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists probe hidden clot risks in autoimmune skin disorders

NCT ID NCT06037187

First seen May 31, 2026 · Last updated Jun 22, 2026 · Updated 3 times

Summary

This study looks at blood clotting in people with autoimmune skin diseases like bullous pemphigoid and lupus. Researchers will collect blood samples from 39 participants—some with active disease and some with mild or controlled disease—plus 15 healthy controls. They will measure clotting factors and inflammation markers to see how these are linked. No treatment is given; the goal is to gather information for future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE BULLOUS DERMATOSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could point toward new ways to monitor or manage clotting risks in autoimmune skin diseases.

What could go wrong

This is a small, early observational study with only 39 participants. It does not test any treatment, so results may not lead to direct patient benefits.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.